Duloxetine Hydrochloride (Cymbalta) + Fluvoxamine Maleate (Luvox)
FDA label language suggests this combination may require monitoring, dose adjustment, or added caution. Make sure every prescriber involved in your care knows you take both.
Basis: Drug interactions section — monitoring/caution language of the Duloxetine Hydrochloride FDA label.
Potent inhibitors of CYP1A2 should be avoided ( 7.1 ) Potent inhibitors of CYP2D6 may increase Duloxetine delayed-release capsules concentrations ( 7.2 ) Duloxetine delayed-release capsules is a moderate inhibitor of CYP2D6 ( 7.9 ) 7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C max was increased about 2.5-fold, and duloxetine t 1/2 was increased
Excerpt from the FDA prescribing label for Duloxetine Hydrochloride (SPL set ID 00628e5e-4c5b-2573-e063-6294a90a0e3b).
About this interaction data. These interactions were identified by automatically scanning FDA prescribing-label text for medications in Bridgeway's library. This is not a complete list and is not a substitute for review by your prescriber or pharmacist, who use comprehensive clinical databases. Always share your full medication list with your care team. How we source this data →
Bridgeway's Utah prescribers coordinate medication management with therapy — so interactions like this one are reviewed by people who see your whole picture.
Request an Appointment Call (801) 255-5131Not medical advice. This page summarizes publicly available FDA drug labeling alongside general guidance from Bridgeway Integrated Healthcare Services. It is for educational purposes only and is not a substitute for advice from your prescriber or pharmacist. Never start, stop, or change a medication without talking to your healthcare provider. In an emergency, call 911.